SCHEMBL2637337

SCHEMBL2637337

O=C1C(Cl)=C(Cl)C(Cl)=C(Cl)C1(Cl)Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.56
TSHR P16473 2/20 0.56
HIF1A Q16665 2/20 0.56
TDP1 Q9NUW8 2/20 0.56
MEN1 O00255 2/20 0.40
RECQL P46063 2/20 0.40
KMT2A Q03164 2/20 0.40
THRB P10828 1/20 0.40
CES2 O00748 2/20 0.35
BCHE P06276 2/20 0.35
ACHE P22303 2/20 0.35
CES1 P23141 2/20 0.35
NSD2 O96028 1/20 0.35
KDM4E B2RXH2 1/20 0.30
TP53 P04637 1/20 0.30
CYP3A4 P08684 1/20 0.30
MAPT P10636 1/20 0.30
HPGD P15428 1/20 0.30
ALOX15 P16050 1/20 0.30
ALOX12 P18054 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7620046 0.88
SCHEMBL9720387 0.77 ALDH1A1 (0.92) ALDH1A1TSHRHIF1ATDP1MEN1
SCHEMBL165983 0.73 ALDH1A1 (1.00) ALDH1A1TSHRHIF1ATDP1MEN1
Hydrochloric Acid SCHEMBL10715580 0.70 ALDH1A1 (0.92) ALDH1A1TSHRHIF1ATDP1MEN1
SCHEMBL5025868 0.69 ALDH1A1 (0.62) ALDH1A1TSHRHIF1ATDP1MEN1
SCHEMBL28647953 0.67 CES2 (0.38) ALDH1A1TSHRHIF1ATDP1MEN1
SCHEMBL9164047 0.66 S100A4 (0.55) ALDH1A1TSHRHIF1ATDP1MEN1
Cyclooctane SCHEMBL3271413 0.65 ALDH1A1 (0.79) ALDH1A1TSHRHIF1ATDP1MEN1
SCHEMBL9418712 0.65
SCHEMBL11494558 0.61 MEN1 (0.35) ALDH1A1TSHRHIF1ATDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111868049-B Process for preparing somatostatin modulators 克林提克斯医药股份有限公司 2023-06-30 CN claimed
EP-3740475-B1 PROCESS OF MAKING SOMATOSTATIN MODULATORS CRINETICS PHARMACEUTICALS INC (US) 2022-04-20 EP claimed
US-20210087165-A1 PROCESS OF MAKING SOMATOSTATIN MODULATORS Crinetics Pharmaceuticals, Inc. 2021-03-25 US claimed
EP-3740475-A1 PROCESS OF MAKING SOMATOSTATIN MODULATORS Crinetics Pharmaceuticals, Inc. (US) 2020-11-25 EP claimed
CN-111868049-A Methods of making somatostatin modulators 克林提克斯医药股份有限公司 2020-10-30 CN claimed
US-20200048219-A1 PROCESS OF MAKING SOMATOSTATIN MODULATORS Crinetics Pharmaceuticals, Inc. 2020-02-13 US claimed
US-10464918-B2 Process of making somatostatin modulators Crinetics Pharmaceuticals, Inc. (US) 2019-11-05 US claimed
WO-2019143718-A1 PROCESS OF MAKING SOMATOSTATIN MODULATORS Crinetics Pharmaceuticals, Inc. (US) 2019-07-25 WO claimed
US-20190218202-A1 PROCESS OF MAKING SOMATOSTATIN MODULATORS Crinetics Pharmaceuticals, Inc. 2019-07-18 US claimed
US-8471067-B2 Stereoselective preparation of P-chiral four-co-ordinated phosphorus compound (o-Tolylphenylmethylphosphine oxide) by reacting chiral alcohol, chiral amine or chiral thiol, with P-chiral three-co-ordinated phosphorus compound, in presence of electrophile UNIVERSITY COLLEGE DUBLIN (IE) 2013-06-25 US claimed
WO-2005118603-A1 CHIRAL PHOSPHORUS COMPOUNDS UNIVERSITY COLLEGE DUBLIN (IE) 2005-12-15 WO claimed
EP-0272644-B1 INTERMEDIATES AND THEIR USE IN THE SYNTHESIS OF ORGANIC COMPOUNDS ZAMBON S.p.A. (IT) 1993-04-28 EP claimed
EP-0217375-B1 PROCESS FOR PREPARING OPTICALLY ACTIVE CARBONYL COMPOUNDS ZAMBON S.p.A. (IT) 1991-01-16 EP claimed
US-4973696-A Stereoselective process for preparing optically active alpha, beta-disubstituted carbonyl compounds ZAMBON S.P.A. (IT) 1990-11-27 US claimed
EP-0210589-B1 PROCESS FOR PREPARING OPTICALLY ACTIVE ALPHA-HALOGEN KETALS ZAMBON S.p.A. (IT) 1990-09-26 EP claimed
US-4764641-A Process for preparing optically active carbonyl compounds ZAMBON SPA (IT) 1988-08-16 US claimed
EP-0158913-B1 PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE ALPHA-ARYLALKANOIC ACIDS AND INTERMEDIATES THEREOF ZAMBON S.p.A. (IT) 1988-07-20 EP claimed
US-4697036-A HALOGENATION, REARRANGEMENT ZAMBON S.P.A. (IT) 1987-09-29 US claimed
EP-0217375-A2 Process for preparing optically active carbonyl compounds ZAMBON S.p.A. (IT) 1987-04-08 EP claimed
EP-0158913-A2 Process for the preparation of optically active alpha-arylalkanoic acids and intermediates thereof ZAMBON S.p.A. (IT) 1985-10-23 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10464918-B2 Process of making somatostatin modulators SSTR5, SSTR4, SSTR2 ALDH1A1 4601/4885TSHR 47/4885HIF1A 667/4885
US-20190218202-A1 PROCESS OF MAKING SOMATOSTATIN MODULATORS SSTR5, SSTR4, SSTR2 ALDH1A1 4601/4885TSHR 47/4885HIF1A 667/4885
US-20210087165-A1 PROCESS OF MAKING SOMATOSTATIN MODULATORS SSTR5, SSTR4, SSTR2 ALDH1A1 4601/4885TSHR 47/4885HIF1A 667/4885
US-20200048219-A1 PROCESS OF MAKING SOMATOSTATIN MODULATORS SSTR5, SSTR4, SSTR2 ALDH1A1 4601/4885TSHR 47/4885HIF1A 667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.